Cardiol Therapeutics Class Stock Analysis

CRDL Stock  USD 2.41  0.05  2.12%   
Cardiol Therapeutics Class is undervalued with Real Value of 2.81 and Target Price of 4.49. The main objective of Cardiol Therapeutics stock analysis is to determine its intrinsic value, which is an estimate of what Cardiol Therapeutics Class is worth, separate from its market price. There are two main types of Cardiol Therapeutics' stock analysis: fundamental analysis and technical analysis.
The Cardiol Therapeutics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA.
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cardiol Therapeutics Class. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.

Cardiol Stock Analysis Notes

The company recorded a loss per share of 0.34. Cardiol Therapeutics had not issued any dividends in recent years. Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease . Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada. Cardiol Therapeutics is traded on NASDAQ Exchange in the United States. For more info on Cardiol Therapeutics Class please contact MBA MBA at 289 910 0850 or go to https://www.cardiolrx.com.

Cardiol Therapeutics Investment Alerts

Cardiol Therapeutics is way too risky over 90 days horizon
Cardiol Therapeutics appears to be risky and price may revert if volatility continues
Net Loss for the year was (28.13 M) with profit before overhead, payroll, taxes, and interest of 78.76 K.
Cardiol Therapeutics Class currently holds about 70.45 M in cash with (25.18 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.14.
Cardiol Therapeutics has a frail financial position based on the latest SEC disclosures
Latest headline from news.google.com: Surging Biotech MA Reaffirms Massive Opportunity In Rare Disease Drug Development - WICZ

Cardiol Therapeutics Upcoming and Recent Events

26th of March 2024
Upcoming Quarterly Report
View
20th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
26th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

Cardiol Largest EPS Surprises

Earnings surprises can significantly impact Cardiol Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2021-08-17
2021-06-30-0.14-0.16-0.0214 
2019-05-08
2019-03-31-0.0676-0.0973-0.029743 
2023-11-14
2023-09-30-0.12-0.090.0325 
View All Earnings Estimates

Cardiol Therapeutics Environmental, Social, and Governance (ESG) Scores

Cardiol Therapeutics' ESG score is a quantitative measure that evaluates Cardiol Therapeutics' performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of Cardiol Therapeutics' operations that may have significant financial implications and affect Cardiol Therapeutics' stock price as well as guide investors towards more socially responsible investments.

Cardiol Stock Institutional Investors

Shares
Susquehanna International Group, Llp2024-03-31
45.7 K
Marble Harbor Investment Counsel, Llc2024-03-31
36.9 K
Advisor Group Holdings, Inc.2024-03-31
25.6 K
Goldman Sachs Group Inc2024-03-31
23.5 K
Two Sigma Advisers, Llc2024-03-31
16.5 K
Royal Bank Of Canada2024-03-31
16.4 K
Private Ocean, Llc2024-03-31
15.2 K
Two Sigma Securities, Llc2024-03-31
14.7 K
Townsquare Capital Llc2024-03-31
12.7 K
Mmcap International Inc. Spc2024-03-31
2.6 M
Tejara Capital Ltd2024-03-31
1.6 M
Note, although Cardiol Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Cardiol Market Capitalization

The company currently falls under 'Small-Cap' category with a current market capitalization of 166.29 M.

Cardiol Profitablity

Last ReportedProjected for Next Year
Return On Tangible Assets(0.77)(0.81)
Return On Capital Employed(1.05)(1.10)
Return On Assets(0.77)(0.80)
Return On Equity(1.00)(1.05)

Management Efficiency

Cardiol Therapeutics has return on total asset (ROA) of (0.4535) % which means that it has lost $0.4535 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.9211) %, meaning that it created substantial loss on money invested by shareholders. Cardiol Therapeutics' management efficiency ratios could be used to measure how well Cardiol Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return On Tangible Assets is estimated to slide to -0.81. The value of Return On Capital Employed is expected to slide to -1.1. At this time, Cardiol Therapeutics' Total Assets are quite stable compared to the past year. Non Current Assets Total is expected to rise to about 610.6 K this year, although the value of Non Currrent Assets Other are projected to rise to (0.95).
Last ReportedProjected for Next Year
Book Value Per Share 0.44  0.64 
Tangible Book Value Per Share 0.43  0.63 
Enterprise Value Over EBITDA(1.26)(1.32)
Price Book Value Ratio 2.55  2.42 
Enterprise Value Multiple(1.26)(1.32)
Price Fair Value 2.55  2.42 
Enterprise Value37.3 M60.7 M
The analysis of Cardiol Therapeutics' management efficiency is an essential part of evaluating and assessing the financial and operational performance of the entity. It is also vital to analyze Cardiol Therapeutics' future growth prospects and the overall market conditions to determine the value and potential of its stock. The analysis involves studying a range of financial metrics such as revenue, earnings, profit margins, cash flow, debt, market share, and external factors such as economic trends, industry outlook, competition, and government regulations. The goal of Cardiol Stock analysis is to determine whether it is undervalued, fairly valued, or overvalued and to make informed investment decisions.
Beta
0.633
Return On Assets
(0.45)
Return On Equity
(0.92)

Technical Drivers

As of the 18th of June 2024, Cardiol Therapeutics shows the Mean Deviation of 4.73, risk adjusted performance of 0.1097, and Downside Deviation of 6.68. Cardiol Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Cardiol Therapeutics treynor ratio, as well as the relationship between the downside variance and kurtosis to decide if Cardiol Therapeutics is priced correctly, providing market reflects its regular price of 2.41 per share. Please also double-check Cardiol Therapeutics Class total risk alpha, which is currently at 0.6719 to validate the company can sustain itself at a future point.

Cardiol Therapeutics Price Movement Analysis

Execute Study
The output start index for this execution was thirteen with a total number of output elements of fourty-eight. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Cardiol Therapeutics middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Cardiol Therapeutics. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.

Cardiol Therapeutics Predictive Daily Indicators

Cardiol Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Cardiol Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Cardiol Therapeutics Corporate Filings

6K
13th of June 2024
A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges.
ViewVerify
6K
28th of May 2024
A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges.
ViewVerify
6K
14th of May 2024
A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges.
ViewVerify
6K
26th of April 2024
A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges.
ViewVerify
6K
2nd of April 2024
A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges.
ViewVerify
1st of April 2024
Other Reports
ViewVerify
6K
26th of February 2024
A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges.
ViewVerify
6K
21st of February 2024
A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges.
ViewVerify

Cardiol Therapeutics Forecast Models

Cardiol Therapeutics' time-series forecasting models are one of many Cardiol Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Cardiol Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Cardiol Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Cardiol Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Cardiol shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Cardiol Therapeutics. By using and applying Cardiol Stock analysis, traders can create a robust methodology for identifying Cardiol entry and exit points for their positions.
Last ReportedProjected for Next Year
Pretax Profit Margin(361.53)(379.61)
Operating Profit Margin(519.63)(545.61)
Net Loss(361.53)(379.61)

Current Cardiol Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Cardiol analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Cardiol analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
4.49Strong Buy4Odds
Cardiol Therapeutics Class current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Cardiol analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Cardiol stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Cardiol Therapeutics, talking to its executives and customers, or listening to Cardiol conference calls.
Cardiol Analyst Advice Details

Cardiol Stock Analysis Indicators

Cardiol Therapeutics Class stock analysis indicators help investors evaluate how Cardiol Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Cardiol Therapeutics shares will generate the highest return on investment. By understating and applying Cardiol Therapeutics stock analysis, traders can identify Cardiol Therapeutics position entry and exit signals to maximize returns.
Begin Period Cash Flow59.4 M
Common Stock Shares Outstanding64.5 M
Total Stockholder Equity28.2 M
Property Plant And Equipment Net337.1 K
Cash And Short Term Investments34.9 M
Cash34.9 M
Accounts Payable7.6 M
Net Debt-34.7 M
50 Day M A2.1571
Total Current Liabilities8.3 M
Other Operating Expenses29.8 M
Non Current Assets Total547.4 K
Non Currrent Assets Other-1.00
Stock Based Compensation4173.21

Additional Information and Resources on Investing in Cardiol Stock

When determining whether Cardiol Therapeutics is a strong investment it is important to analyze Cardiol Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Cardiol Therapeutics' future performance. For an informed investment choice regarding Cardiol Stock, refer to the following important reports:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cardiol Therapeutics Class. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.
You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cardiol Therapeutics. If investors know Cardiol will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cardiol Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.34)
Return On Assets
(0.45)
Return On Equity
(0.92)
The market value of Cardiol Therapeutics is measured differently than its book value, which is the value of Cardiol that is recorded on the company's balance sheet. Investors also form their own opinion of Cardiol Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Cardiol Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cardiol Therapeutics' market value can be influenced by many factors that don't directly affect Cardiol Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cardiol Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cardiol Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cardiol Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.